Active, not recruitingPhase 3NCT05198557

A Study of MT-0551 in Patients With Systemic Sclerosis

Studying Diffuse cutaneous systemic sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Tanabe Pharma Corporation
Principal Investigator
General Manager
Tanabe Pharma Corporation
Intervention
Inebilizumab(drug)
Enrollment
80 enrolled
Eligibility
20-80 years · All sexes
Timeline
20222026

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05198557 on ClinicalTrials.gov

Other trials for Diffuse cutaneous systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Diffuse cutaneous systemic sclerosis

← Back to all trials